PERSEPHONE: a randomised phase 3 non-inferiority trial of 6 versus 12 months (m) of adjuvant trastuzumab in patients with HER2 positive (+) early breast cancer (EBC)
Authors
Earl, HHiller, L
Vallier, L
Loi, S
Howe, D
Higgins, H
McAdam, K
Hughes-Davies, L
Harnett, A
Ah-See, L
Simcock, R
Rea, D
Mansi, J
Abraham, J
Caldas, C
Hulme, C
Miles, D
Wardley, Andrew M
Cameron, D
Dunn, J
Affiliation
MCRC Biobank, The Christie NHS Foundation Trust, ManchesterIssue Date
2018